Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Abstract
Achieving mucosal healing in patients with inflammatory bowel disease is related to a higher incidence of sustained clinical remission and it translates to lower rates of hospitalisation and surgery. The assessment methods of disease activity and response to therapy are limited and mainly rely on colonoscopy. This meta-analysis reviews the effectiveness of using faecal calprotectin as a marker for mucosal healing in inflammatory bowel disease. Two meta-analyses were conducted in parallel. The analysis on the use of faecal calprotectin in monitoring mucosal healing in colonic Crohn’s disease is based on 16 publications (17 studies). The data set for diagnostic values of faecal calprotectin in ulcerative colitis is composed of 35 original publications (total 49 studies). The DOR for the use of faecal calprotectin in Crohn’s disease is estimated to be 11.20 and the area under the sROCis 0.829. In cases of ulcerative colitis, the DOR is 14.48, while the AUC sROC is 0.858. Heterogeneity of the studies was moderatetosubstantial. Collected data show overall good sensitivity and specificity of the faecal calprotectin test, as well as a good DOR. Thus, monitoring of mucosal healing with a non-invasive faecal calprotectin test may represent an attractive option for physicians and patients with inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is an established, sensitive marker used to monitor IBD activity and, by extension, reflects microbiota-driven mucosal inflammation.119,121,122”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902 · cited 7×
“Authors collected data from hundreds of UC patients participating in a phase 4 trial and performed a post-hoc analysis with two MH definitions (MES = 0, MES ≤ 1).”
MethodInfluentialReitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369 · cited 1×
“The univariate effects model predicts the DOR to be higher than that estimated with the use of the bivariate model based on the Reitsma’s method [77].”
MethodCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026 · cited 7×
“Authors collected data from hundreds of UC patients participating in a phase 4 trial and performed a post-hoc analysis with two MH definitions (MES = 0, MES ≤ 1).”
MethodInfluentialMagro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910 · cited 1×
“The concept of deep remission (DR) is complex, and a standardised definition of DR is still missing [6].”
BackgroundPeyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844 · cited 1×
“In addition, for CD, the resolution of inflammation-related findings on imaging in patients who cannot be adequately assessed with ileocolonoscopy [4,5].”
BackgroundMaaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774 · cited 8×
“This could be explained by the fact that SES-CD is a simplified, easier to calculate version of CDEIS.”
MethodInfluential
Cited by
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334395 · Cited by 169
Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review
Langley, B. O., Guedry, S. E., Goldenberg, J. Z., Hanes, D. A., Beardsley, J., & Ryan, J. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184219 · Cited by 76
Kraszewski, S., Szczurek, W., Szymczak, J., Reguła, M., & Neubauer, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204745 · Cited by 60
Self-citationŚlósarz, D., Poniewierka, E., Neubauer, K., & Kempiński, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184044 · Cited by 33
“Furthermore, assessment of the effectiveness of treatment strategy requires endoscopy as other indices of mucosal healing (MH) are still unavailable [6].”
BackgroundSelf-citationFecal Calprotectin in Gastrointestinal Disease
Murray, J. L., Kok, K. B., & Ayling, R. M. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad051 · Cited by 40
Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
Wetwittayakhlang, P., Lontai, L., Gönczi, L., Golovics, P. A., Hahn, G. D., Bessissow, T., & Lakatos, P. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235551 · Cited by 36
“Although the included studies used a wide range of cutoff values (14 to 251 μg/g) [40].”
BackgroundMethodProbiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?
Filidou, E., & Kolios, G. C. (2021) · Pharmaceuticals · doi:10.3390/ph14111181 · Cited by 34
“In addition, newer markers, such as fecal calprotectin, magnetic resonance enterography, and capsule endoscopy are also used to define clinical remission and mucosal healing [35,36].”
BackgroundGut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease
Kumrić, M., Živković, P. M., Kurir, T. T., Vrdoljak, J., Vilović, M., Martinović, D., Bratanić, A., Lizatovic, I. K., & Božić, J. (2021) · Diagnostics · doi:10.3390/diagnostics12010045 · Cited by 30
“Currently, the most widely accepted IBD biomarker is fecal calprotectin, a calcium and zinc binding protein, representing about 60% of soluble proteins of the cytoplasm of granulocytes [10].”
BackgroundCosta, M. H. D. M., Sassaki, L. Y., & Chebli, J. M. F. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i24.3022 · Cited by 22
“…various FC cutoff values to correspond to MH (13.9-251 μg/g) in UC, although the most common values were between 150 and 250 μg/g. Similarly, no universal cutoff value for FC in CD was identified, with the reported range relatively wide, ranging from 54-918 μg/g, with a mean cutoff of 205 μg/g[36].”
InfluentialRohatinsky, N., Zelinsky, S., Dolinger, M. T., Christensen, B., Wilkens, R., Radford, S. J., Dubinsky, M. C., & Novak, K. L. (2023) · Crohn s & Colitis 360 · doi:10.1093/crocol/otad012 · Cited by 24
Diagnostic accuracy of calprotectin in periprosthetic joint infection: a diagnostic meta-analysis
Xing, J., Li, J., Yan, Z., Li, Y., Liu, X., He, L., Xu, T., Wang, C., Zhao, L., & Ke, J. (2022) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02895-4 · Cited by 18
“In the previous literature, CLP had been reported to predict or evaluate the progress of inflammatory diseases such as inflammatory bowel disease (IBD) [27, 28], rheumatoid arthritis [29, 30], and spondyloarthritis [31].”
BackgroundWu, J., Li, M., Zhou, C., Rong, J., Zhang, F., Wen, Y., Qu, J., Wu, R. J., Miao, Y., & Niu, J. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09513-5 · Cited by 21
Cai, W., Xu, J., Chen, Y., Wu, X. H., Zeng, Y., & Yu, F. (2023) · Inflammation · doi:10.1007/s10753-023-01827-0 · Cited by 18
“Currently, endoscopy examination is the gold standard for monitoring disease course, response to therapy, and evaluating disease activity [7, 8].”
BackgroundMathew, N. E., McCaffrey, D., Walker, A. K., Mallitt, K., Masi, A., Morris, M. J., & Ooi, C. Y. (2024) · Molecular Autism · doi:10.1186/s13229-023-00575-0 · Cited by 20
Labes, S., Froy, O., Tabach, Y., Shamir, R., Shouval, D. S., & Weintraub, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031488 · Cited by 8
Review Article: Green Management of IBD —New Paradigms for an Eco‐Friendly Approach
Cammarota, G., Laterza, L., Bibbò, S., Fusco, W. G., Rozera, T., Brino, E. D., Porcari, S., Scaldaferri, F., Ianiro, G., Gasbarrini, A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18399 · Cited by 6
Wetwittayakhlang, P., Golovics, P. A., Khoury, A. A., Ganni, E., Hahn, G. D., Cohen, A., Wyse, J. M., Bradette, M., Bessissow, T., Afif, W., et al. (2022) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4375 · Cited by 6
“Although, FCAL level is a better predictor for detecting endoscopic mucosal healing and clinical relapse than CRP [22-25], serial FCAL monitoring was a suboptimal assessment and remained challenging in clinical practice.”
BackgroundInfluentialChurchhouse, A. M. D., Moffat, V. E., Selinger, C. P., Lamb, C. A., THORNTON, M. J., Penman, I. D., & Din, S. (2022) · Gut · doi:10.1136/gutjnl-2022-328309 · Cited by 5
“23 Patients with a high faecal calpro-tectin are also likely to have a high qFIT suggesting active IBD and therefore optimising IBD treatment before conducting a surveillance procedure would be a reasonable approach, given the challenges of surveying an inflamed colon and the association with PCCRC…”
Wetwittayakhlang, P., Kotrri, G., Bessissow, T., & Lakatos, P. L. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371049 · Cited by 3
“Furthermore, a recent meta-analysis comprising 49 studies of UC patients supported the use of FCAL in predicting endoscopic remission, with a sensitivity of 78% and specificity of 79%, using the most common FCAL cutoff levels between 150–250 mcg/g [27].”
MethodMemristor-based Bayesian spiking neural network for IBD diagnosis
Li, X., Wu, Q., Chen, Y., Jin, Y., Ma, J., & Yang, J. (2024) · Knowledge-Based Systems · doi:10.1016/j.knosys.2024.112099 · Cited by 1
Mucosal Healing Research Advances of Inflammatory Bowel Disease
Zhang, C., Ming, D., & Ji, G. (2024) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2024.06(09).32 · Cited by 1
Kamp, K., Hendrickson, K., Iqbal, A., Saad, K., Clark‐Snustad, K., Dey, N., Gui, X. S., & Lee, S. (2025) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000878 · Cited by 1
Gubergrits, N. B. (2022) · Modern Gastroenterology · doi:10.30978/mg-2022-3-23
Fecal Markers in Inflammatory Bowel Disease
Niklinska-Schirtz, B. J., & Sauer, C. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-14744-9_19
Faecal Calprotectin Diagnostics: Focus on Primary Care and Suspected Sources of Error
Rendek, Z. (2023) · Linköping University medical dissertations · doi:10.3384/9789179294014
“Recent meta-analyses (82, 83) have evaluated the applicability of FC as a noninvasive biomarker of mucosal healing in IBD, and the results were promising.”
BackgroundClassification and prediction of inflammatory bowel diseases
Kumar, S. (2023) · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · doi:10.55041/ijsrem27527
Fellak, N. (2024) · International Journal of Health Sciences · doi:10.53730/ijhs.v8ns1.14756
Memristor-Based Bayesian Spiking Neural Network for Ibd DiagnosisPreprint
ma, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4778908
Xing, J., Li, J., Yan, Z., Li, Y., Liu, X., He, L., Xu, T. S., Wang, C., Zhao, L., & Ke, J. (2022) · Figshare · doi:10.6084/m9.figshare.17982257
Mucosal Healing Research Advances of Inflammatory Bowel Disease
Zhang, C., Ming, D., & Ji, G. (2024) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2024.06(09).30
Tan, H., Chen, M., Yao, H., Li, S., & Nie, S. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c09097 · Cited by 1
Mathew, N. E., McCaffrey, D., Walker, A. K., Mallitt, K.-A., Masi, A., Morris, M. J., & Ooi, C. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26668833
Mathew, N. E., McCaffrey, D., Walker, A. K., Mallitt, K.-A., Masi, A., Morris, M. J., & Ooi, C. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26668827
Mathew, N. E., McCaffrey, D., Walker, A. K., Mallitt, K.-A., Masi, A., Morris, M. J., & Ooi, C. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26668830
The Contribution of Endoscopy in IBD
Badre, W., Rhaoussi, F. Z. E., & Tahiri, M. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014215
García-Rodrigo, L., Ramos-López, C., Sánchez‐Tirado, E., Agüí, L., & González-Cortés, A. (2026) · Biosensors · doi:10.3390/bios16040199
“Combined detection enables differentiation between epithelial-driven injury and immune-mediated responses, providing a more comprehensive assessment of IBD pathophysiology [7,10].”
Tita, G., Fogaş, C. R., Slăvescu, K. C., Tantau, M. V., Medan, S. A., & Serban, D. E. (2026) · Biomolecules · doi:10.3390/biom16060801
“FC values ≥ 250 µ g/g were considered indicative of microscopic activity, while MH was defined as FC values below 250 µ g/g [20].”
Zhang, Y., Zhang, Z., Sun, H., Diao, B., Ma, D., Wang, D., Jia, J., Jin, W., & Huang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1903539
Serum amyloid a as a high-resolution indicator of mucosal healing in ulcerative colitis
Akita, K., Yokoyama, Y., Shimomori, Y., Kazama, T., Nojima, M., & Nakase, H. (2026) · Crohn s & Colitis 360 · doi:10.1093/crocol/otag097
Metadata
- Authors
- Bromke, M. A., Neubauer, K., Kempiński, R., & Krzystek-Korpacka, M.
- Affiliations
- Wroclaw Medical University (PL)
- Department of Biochemistry and Immunochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland
- Corresponding author
- Bromke, Mariusz A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-05-19
- Volume
- 10
- Issue
- 10
- Pages
- 2203
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8161009
- OpenAlex
- W3161643431
- Cited by
- 39
- References
- 86
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 14 · 2023: 6 · 2022: 4 · 2021: 6
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- fecal calprotectin, mucosal healing, inflammatory bowel disease, Crohn's disease, ulcerative colitis, non-invasive biomarkers, disease activity monitoring, diagnostic accuracy, diagnostic odds ratio, sensitivity and specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.